MannKind (MNKD) Will Release Earnings After The Bell | What To Expect

0

MannKind Stock NewsMannKind Corporation (NASDAQ: MNKD)

MannKind is expected to release its earnings report today after the bell. As investors anticipate the report, the stock price is taking a bit of a dive today. So below, we’ll talk about what we can expect from the earnings report, what we’re seeing in the market today, and what we can expect to see moving forward. So, lets get right to it…

What To Expect From MNKD Earnings

As with any earnings report, investors will be looking for top line revenue, earnings per share, guidance, and more. Here’s what I think we’ll see…

  • Earnings Per Share – Based on analyst projections, a high earnings per share would come in at a loss of $0.07, while on the low end, it should come in around a loss of $0.11 with the average expectation being a loss of $0.08. Personally, I think we’re going to come in on the high end of the range; somewhere between a loss of $0.05 and $0.07.
  • Revenue – In the quarter, analysts are expecting that MNKD generated around $4.26 million. While I don’t have an exact estimate, I am predicting that MNKD will beat this estimate. Based on the landmark the company reached with Afrezza.
  • Afrezza Sales – All eyes will be on Afrezza sales upon the release of the report. We do know that the inhaled insulin has broke the $1 million in sales mark; but we don’t know exactly how much has been sold. So, I’ll be watching closely to see where Afrezza stands.


Subscribe to The Prudent Speculator

What We’re Seeing From MNKD Today

Based on what we’re seeing in the market today, it seems as though investors have a negative impression with regard to expectations for the report. Unfortunately, MNKD is seeing red in the market today. Currently (10:54), MNKD is trading at $4.13 per share after a loss of 0.72%.

What We Can Expect Moving Forward

Moving forward, I’m expecting to see great things in the short term and long term outlook. In the short run, I’m expecting to see an overwhelmingly positive first quarter earnings report drive the price of the stock up. In the long run, I see incredible value in Afrezza. I’m also relatively impressed by the pipeline MNKD has been working on. Finally, the technology used to deliver insulin in Afrezza may also be used to deliver other medications in the future; this could prove to be incredibly popular. Over all, I’m expecting to see massive long term gains.

What Do You Think?

Where do you think MNKD is headed and why? Let us know in the comments below!

LEAVE A REPLY

Please enter your comment!
Please enter your name here